Cardiocirculatory compromised COVID-19 patients receiving high doses of norepinephrine (>0.3 μg/kg/min, n = 6) showed much lower BChE activity compared to those who needed low-dose norepinephrine support (<0.3 μg/kg/min, n = 42) (BChE activity in cardiocirculatory compromised COVID-19 patients with norepinephrine >0.3 μg/kg/min (n = 6): 530 U/l (373–1.275) vs. critically ill COVID-19 patients with norepinephrine <0.3 μg/kg/min (n = 42): 1.113 U/l (871–1.496), p < 0.05; Figure 4). The gene discussed is BCHE; the disease is COVID-19.